Insurance Claims Adjuster, Claims News, LEGAL/JUDGEMENTS, Noven Files Patent Infringement Lawsuit against Watson Pharmaceuticals Claims-Portal.com

Become a member and contribute content to Claims-Portal.com Add your company to the Claims-Portal.com Vendor Directory Add job openings to the Claims-Portal.com Career Center
Claims-Portal.comClaims News
My Claims-Portal
Nov 20, 2017    
 - Member Benefits
 - Become a Member
 - About Us
 - Advertising

this page!
Independent Adjusters
Employers/Recruiters
Claims Software

Browse Categories
Claims News Sections
  INSURANCE/CLAIMS
  LEGAL/JUDGEMENTS
  WEATHER/CATS
Announcements
  Association Announcements
  Business Announcements
  NAIIA Member Announcements
  Other Categories
 
C2Track Claims Management System

News » LEGAL/JUDGEMENTS News

Print Story

Noven Files Patent Infringement Lawsuit against Watson Pharmaceuticals

advertisement
Dyanclaim for Claims Websites

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Watson Pharmaceuticals ("Watson") for infringement of certain Noven patents (the "Patents") by Watson.

The lawsuit was filed as a result of an Abbreviated New Drug Application (ANDA) submission by Watson seeking FDA approval to market and sell a generic version of Daytranaģ (methylphenidate transdermal system) prior to the scheduled expiration of the Patents in 2018. The lawsuit reflects Novenís commitment to vigorously defending its intellectual property rights against infringement.

Under the Hatch-Waxman Act, because Noven filed this patent infringement lawsuit within 45 days of receiving a Paragraph IV notification letter from Watson, the FDA cannot approve Watsonís ANDA for 30 months (until March 2014), unless the district court finds the Patents invalid or not infringed before the 30 months pass.

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Novenís business and operations are focused in three principal areas Ė transdermal drug delivery and related manufacturing, the Novogyne joint venture, and Noven Therapeutics, Novenís specialty pharmaceutical unit. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., and serves as Hisamitsuís U.S. growth platform in prescription pharmaceuticals. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.

Print Story
Send This Story To Someone
Your Email:
Their Email:
  Comments:
 

Claims News Home Page   |   RSS Feeds
Announcements   |   Member Blogs   |   Newsletters   |   Letters
Submit A News Story   |   Contact The Editor

  •  Announcements
  •  Claims Events
  •  Insurance News
  •  Special Offers
  •  Newsletters
  •  Blogs
  •  RSS Feeds
  •  Directory
  •  insURLinks
  •  Classifieds
  •  About Us
  •  Contact Us
  •  Advertising
  •  Member Search

  •  Registration
  •  Login
  •  E-Mail Lists
  • Home  |   Privacy Policy  |   Terms of Service  |   Site Map
    © 1998-2017 E-Claim.com, LLC